Listed

Pfizer Inc

PFENYSECIK 78003HealthcareFiscal year ends Dec 31

Latest reported revenue, Q2 FY2026$15.03bnRevenue, Q2 FY2026, three months to 2026-06-28$15.03bn. XBRL concept us-gaap:Revenues. 10-Q filed 2026-08-04, accession 0000078003-26-000095.Report this figureThree months to Jun 28, 2026, from the 10-Q filed Aug 4, 2026.

Latest quarter: Q2 FY2026

Three months to Jun 28, 2026, against the same quarter a year earlier.

  • Revenue$15.03bnRevenue, Q2 FY2026, three months to 2026-06-28$15.03bn. XBRL concept us-gaap:Revenues. 10-Q filed 2026-08-04, accession 0000078003-26-000095.Report this figure+2.6% on a year earlier
  • Gross marginnot reported (Gross profit not reported)No year-earlier figure to compare
  • Operating marginnot reported (Operating income not reported)No year-earlier figure to compare
  • Net margin−1.6%Net margin, Q2 FY2026, three months to 2026-06-28. net income / revenueNet income: −$248.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-04, accession 0000078003-26-000095.Revenue: $15.03bn. XBRL concept us-gaap:Revenues. 10-Q filed 2026-08-04, accession 0000078003-26-000095.Report this figure−21.5 pts on a year earlier
  • Diluted EPS−$0.04Diluted EPS, Q2 FY2026, three months to 2026-06-28−$0.04 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-04, accession 0000078003-26-000095.Report this figureSign changed from a year earlier
  • Free cash flow$302.0mFree cash flow, Q2 FY2026, three months to 2026-06-28. operating cash flow − capital expenditureOperating cash flow: $835.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-04, accession 0000078003-26-000095. Derived: 6-month figure less the 3-month figure.Capital expenditure: $533.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-04, accession 0000078003-26-000095. Derived: 6-month figure less the 3-month figure.Report this figureSign changed from a year earlier

Last eight quarters

Full statements
Revenue$15.03bnNet margin −1.6%
Diluted EPS−$0.04, Q2 FY2026
Free cash flow$302.0m, Q2 FY2026
Pfizer Inc, key figures for the last eight quarters
Line itemUnitQ3 FY20242024-09-29Q4 FY20242024-12-31Q1 FY20252025-03-30Q2 FY20252025-06-29Q3 FY20252025-09-28Q4 FY20252025-12-31Q1 FY20262026-03-29Q2 FY20262026-06-28Shape over the periods
Revenue$bn17.7Revenue, Q3 FY2024, three months to 2024-09-29$17.70bn. XBRL concept us-gaap:Revenues. 10-Q filed 2025-11-04, accession 0000078003-25-000150.Report this figure17.8Revenue, Q4 FY2024, three months to 2024-12-31$17.76bn. XBRL concept us-gaap:Revenues. 10-K filed 2026-02-26, accession 0000078003-26-000026. Derived: 12-month figure less the 9-month figure.Report this figure13.7Revenue, Q1 FY2025, three months to 2025-03-30$13.71bn. XBRL concept us-gaap:Revenues. 10-Q filed 2026-05-05, accession 0000078003-26-000054.Report this figure14.7Revenue, Q2 FY2025, three months to 2025-06-29$14.65bn. XBRL concept us-gaap:Revenues. 10-Q filed 2026-08-04, accession 0000078003-26-000095.Report this figure16.7Revenue, Q3 FY2025, three months to 2025-09-28$16.65bn. XBRL concept us-gaap:Revenues. 10-Q filed 2025-11-04, accession 0000078003-25-000150.Report this figure17.6Revenue, Q4 FY2025, three months to 2025-12-31$17.56bn. XBRL concept us-gaap:Revenues. 10-K filed 2026-02-26, accession 0000078003-26-000026. Derived: 12-month figure less the 9-month figure.Report this figure14.5Revenue, Q1 FY2026, three months to 2026-03-29$14.45bn. XBRL concept us-gaap:Revenues. 10-Q filed 2026-05-05, accession 0000078003-26-000054.Report this figure15.0Revenue, Q2 FY2026, three months to 2026-06-28$15.03bn. XBRL concept us-gaap:Revenues. 10-Q filed 2026-08-04, accession 0000078003-26-000095.Report this figure
Gross margin%not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)
Operating margin%not reported (Operating income not reported)not reported (Operating income not reported)not reported (Operating income not reported)not reported (Operating income not reported)not reported (Operating income not reported)not reported (Operating income not reported)not reported (Operating income not reported)not reported (Operating income not reported)
Net margin%25.2%Net margin, Q3 FY2024, three months to 2024-09-29. net income / revenueNet income: $4.46bn. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-04, accession 0000078003-25-000150.Revenue: $17.70bn. XBRL concept us-gaap:Revenues. 10-Q filed 2025-11-04, accession 0000078003-25-000150.Report this figure2.3%Net margin, Q4 FY2024, three months to 2024-12-31. net income / revenueNet income: $410.0m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-26, accession 0000078003-26-000026. Derived: 12-month figure less the 9-month figure.Revenue: $17.76bn. XBRL concept us-gaap:Revenues. 10-K filed 2026-02-26, accession 0000078003-26-000026. Derived: 12-month figure less the 9-month figure.Report this figure21.6%Net margin, Q1 FY2025, three months to 2025-03-30. net income / revenueNet income: $2.97bn. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-05, accession 0000078003-26-000054.Revenue: $13.71bn. XBRL concept us-gaap:Revenues. 10-Q filed 2026-05-05, accession 0000078003-26-000054.Report this figure19.9%Net margin, Q2 FY2025, three months to 2025-06-29. net income / revenueNet income: $2.91bn. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-04, accession 0000078003-26-000095.Revenue: $14.65bn. XBRL concept us-gaap:Revenues. 10-Q filed 2026-08-04, accession 0000078003-26-000095.Report this figure21.3%Net margin, Q3 FY2025, three months to 2025-09-28. net income / revenueNet income: $3.54bn. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-04, accession 0000078003-25-000150.Revenue: $16.65bn. XBRL concept us-gaap:Revenues. 10-Q filed 2025-11-04, accession 0000078003-25-000150.Report this figure(9.4%)Net margin, Q4 FY2025, three months to 2025-12-31. net income / revenueNet income: −$1.65bn. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-26, accession 0000078003-26-000026. Derived: 12-month figure less the 9-month figure.Revenue: $17.56bn. XBRL concept us-gaap:Revenues. 10-K filed 2026-02-26, accession 0000078003-26-000026. Derived: 12-month figure less the 9-month figure.Report this figure18.6%Net margin, Q1 FY2026, three months to 2026-03-29. net income / revenueNet income: $2.69bn. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-05, accession 0000078003-26-000054.Revenue: $14.45bn. XBRL concept us-gaap:Revenues. 10-Q filed 2026-05-05, accession 0000078003-26-000054.Report this figure(1.6%)Net margin, Q2 FY2026, three months to 2026-06-28. net income / revenueNet income: −$248.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-04, accession 0000078003-26-000095.Revenue: $15.03bn. XBRL concept us-gaap:Revenues. 10-Q filed 2026-08-04, accession 0000078003-26-000095.Report this figure
Diluted EPS$ per share0.78Diluted EPS, Q3 FY2024, three months to 2024-09-29$0.78 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-04, accession 0000078003-25-000150.Report this figurenot reported (Diluted EPS not reported)0.52Diluted EPS, Q1 FY2025, three months to 2025-03-30$0.52 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-05, accession 0000078003-26-000054.Report this figure0.51Diluted EPS, Q2 FY2025, three months to 2025-06-29$0.51 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-04, accession 0000078003-26-000095.Report this figure0.62Diluted EPS, Q3 FY2025, three months to 2025-09-28$0.62 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-04, accession 0000078003-25-000150.Report this figurenot reported (Diluted EPS not reported)0.47Diluted EPS, Q1 FY2026, three months to 2026-03-29$0.47 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-05, accession 0000078003-26-000054.Report this figure(0.04)Diluted EPS, Q2 FY2026, three months to 2026-06-28−$0.04 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-04, accession 0000078003-26-000095.Report this figure
Free cash flow$bn6.1Free cash flow, Q3 FY2024, three months to 2024-09-29. operating cash flow − capital expenditureOperating cash flow: $6.71bn. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-04, accession 0000078003-25-000150. Derived: 9-month figure less the 6-month figure.Capital expenditure: $651.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-04, accession 0000078003-25-000150. Derived: 9-month figure less the 6-month figure.Report this figure5.8Free cash flow, Q4 FY2024, three months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: $6.72bn. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-26, accession 0000078003-26-000026. Derived: 12-month figure less the 9-month figure.Capital expenditure: $917.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-26, accession 0000078003-26-000026. Derived: 12-month figure less the 9-month figure.Report this figure1.8Free cash flow, Q1 FY2025, three months to 2025-03-30. operating cash flow − capital expenditureOperating cash flow: $2.33bn. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-05, accession 0000078003-26-000054.Capital expenditure: $564.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-05, accession 0000078003-26-000054.Report this figure(1.2)Free cash flow, Q2 FY2025, three months to 2025-06-29. operating cash flow − capital expenditureOperating cash flow: −$582.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-04, accession 0000078003-26-000095. Derived: 6-month figure less the 3-month figure.Capital expenditure: $618.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-04, accession 0000078003-26-000095. Derived: 6-month figure less the 3-month figure.Report this figure4.0Free cash flow, Q3 FY2025, three months to 2025-09-28. operating cash flow − capital expenditureOperating cash flow: $4.60bn. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-04, accession 0000078003-25-000150. Derived: 9-month figure less the 6-month figure.Capital expenditure: $602.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-04, accession 0000078003-25-000150. Derived: 9-month figure less the 6-month figure.Report this figure4.5Free cash flow, Q4 FY2025, three months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: $5.35bn. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-26, accession 0000078003-26-000026. Derived: 12-month figure less the 9-month figure.Capital expenditure: $845.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-26, accession 0000078003-26-000026. Derived: 12-month figure less the 9-month figure.Report this figure2.2Free cash flow, Q1 FY2026, three months to 2026-03-29. operating cash flow − capital expenditureOperating cash flow: $2.62bn. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-05, accession 0000078003-26-000054.Capital expenditure: $436.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-05, accession 0000078003-26-000054.Report this figure0.3Free cash flow, Q2 FY2026, three months to 2026-06-28. operating cash flow − capital expenditureOperating cash flow: $835.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-04, accession 0000078003-26-000095. Derived: 6-month figure less the 3-month figure.Capital expenditure: $533.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-04, accession 0000078003-26-000095. Derived: 6-month figure less the 3-month figure.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Last five fiscal years

Revenue$62.58bnNet margin 12.4%
Diluted EPS$1.36, FY2025
Free cash flow$9.07bn, FY2025
Pfizer Inc, key figures for the last five fiscal years
Line itemUnitFY20212021-12-31FY20222022-12-31FY20232023-12-31FY20242024-12-31FY20252025-12-31Shape over the periods
Revenue$bn73.6Revenue, FY2021, twelve months to 2021-12-31$73.64bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-02-22, accession 0000078003-24-000039.Report this figure91.8Revenue, FY2022, twelve months to 2022-12-31$91.79bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-02-22, accession 0000078003-24-000039.Report this figure50.9Revenue, FY2023, twelve months to 2023-12-31$50.91bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-02-22, accession 0000078003-24-000039.Report this figure63.6Revenue, FY2024, twelve months to 2024-12-31$63.63bn. XBRL concept us-gaap:Revenues. 10-K filed 2026-02-26, accession 0000078003-26-000026.Report this figure62.6Revenue, FY2025, twelve months to 2025-12-31$62.58bn. XBRL concept us-gaap:Revenues. 10-K filed 2026-02-26, accession 0000078003-26-000026.Report this figure
Gross margin%not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)
Operating margin%not reported (Operating income not reported)not reported (Operating income not reported)not reported (Operating income not reported)not reported (Operating income not reported)not reported (Operating income not reported)
Net margin%29.8%Net margin, FY2021, twelve months to 2021-12-31. net income / revenueNet income: $21.98bn. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2024-02-22, accession 0000078003-24-000039.Revenue: $73.64bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-02-22, accession 0000078003-24-000039.Report this figure34.2%Net margin, FY2022, twelve months to 2022-12-31. net income / revenueNet income: $31.37bn. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-02-27, accession 0000078003-25-000054.Revenue: $91.79bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-02-22, accession 0000078003-24-000039.Report this figure4.2%Net margin, FY2023, twelve months to 2023-12-31. net income / revenueNet income: $2.12bn. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-26, accession 0000078003-26-000026.Revenue: $50.91bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-02-22, accession 0000078003-24-000039.Report this figure12.6%Net margin, FY2024, twelve months to 2024-12-31. net income / revenueNet income: $8.03bn. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-26, accession 0000078003-26-000026.Revenue: $63.63bn. XBRL concept us-gaap:Revenues. 10-K filed 2026-02-26, accession 0000078003-26-000026.Report this figure12.4%Net margin, FY2025, twelve months to 2025-12-31. net income / revenueNet income: $7.77bn. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-26, accession 0000078003-26-000026.Revenue: $62.58bn. XBRL concept us-gaap:Revenues. 10-K filed 2026-02-26, accession 0000078003-26-000026.Report this figure
Diluted EPS$ per share3.85Diluted EPS, FY2021, twelve months to 2021-12-31$3.85 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2024-02-22, accession 0000078003-24-000039.Report this figure5.47Diluted EPS, FY2022, twelve months to 2022-12-31$5.47 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2025-02-27, accession 0000078003-25-000054.Report this figure0.37Diluted EPS, FY2023, twelve months to 2023-12-31$0.37 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-26, accession 0000078003-26-000026.Report this figure1.41Diluted EPS, FY2024, twelve months to 2024-12-31$1.41 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-26, accession 0000078003-26-000026.Report this figure1.36Diluted EPS, FY2025, twelve months to 2025-12-31$1.36 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-26, accession 0000078003-26-000026.Report this figure
Free cash flow$bn29.9Free cash flow, FY2021, twelve months to 2021-12-31. operating cash flow − capital expenditureOperating cash flow: $32.58bn. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2024-02-22, accession 0000078003-24-000039.Capital expenditure: $2.71bn. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2024-02-22, accession 0000078003-24-000039.Report this figure26.0Free cash flow, FY2022, twelve months to 2022-12-31. operating cash flow − capital expenditureOperating cash flow: $29.27bn. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-02-27, accession 0000078003-25-000054.Capital expenditure: $3.24bn. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-02-27, accession 0000078003-25-000054.Report this figure4.8Free cash flow, FY2023, twelve months to 2023-12-31. operating cash flow − capital expenditureOperating cash flow: $8.70bn. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-26, accession 0000078003-26-000026.Capital expenditure: $3.91bn. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-26, accession 0000078003-26-000026.Report this figure9.8Free cash flow, FY2024, twelve months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: $12.74bn. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-26, accession 0000078003-26-000026.Capital expenditure: $2.91bn. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-26, accession 0000078003-26-000026.Report this figure9.1Free cash flow, FY2025, twelve months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: $11.70bn. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-26, accession 0000078003-26-000026.Capital expenditure: $2.63bn. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-26, accession 0000078003-26-000026.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Insider purchases and sales

All insider transactions

The last 20 open-market transactions reported on Form 4 (codes P and S). The reported price is the price per share the insider stated on the form: filing data, not a market price.

No open-market purchases or sales by insiders are in coverage from Nov 2024 to Oct 2026.

No open-market purchases or sales by insiders are in coverage for this company.

Funds that report holding it

All funds

From each manager's latest Form 13F, largest reported value first. Reported value is as filed at the quarter end: filing data, not a price. A put or call is an option position, not shares held.

Funds that report holding Pfizer Inc
FundQuarter endedReported valueSharesPut or callChange on the quarter before
BlackRock, Inc.2026-06-30$12.75bn529,670,433Added+31,412,883
VANGUARD CAPITAL MANAGEMENT LLC2026-06-30$8.96bn372,149,852Added+2,719,840
STATE STREET CORP2026-06-30$7.39bn307,090,897Added+5,501,032
GEODE CAPITAL MANAGEMENT, LLC2026-06-30$3.25bn135,275,782Added+1,714,040
VANGUARD PORTFOLIO MANAGEMENT LLC2026-06-30$2.87bn119,235,030Added+2,500,335
Fisher Asset Management, LLC2026-06-30$2.63bn109,067,291Added+4,102,864
MORGAN STANLEY2026-06-30$2.32bn96,345,452Added+3,660,082
NORGES BANK2026-06-30$1.48bn61,505,586New+61,505,586
NORTHERN TRUST CORP2026-06-30$1.42bn59,084,573Reduced−2,941,979
Bank of New York Mellon Corp2026-06-30$1.39bn57,879,546Added+3,999,646

Recent filings

All 4,571 filings

Reports and events: 10-K, 10-Q, 8-K, proxy statements and ownership schedules.

Pfizer Inc, recent filings
FiledFormWhat it isAccession number
2026-08-0411:04 ET10-QQuarterly reportPeriod 2026-06-280000078003-26-000095
2026-08-0411:02 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0000078003-26-000094
2026-06-1817:17 ET8-K7.01 Regulation FD disclosure0000078003-26-000087
2026-06-1811:07 ET8-K5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits0000078003-26-000085
2026-05-0511:03 ET10-QQuarterly reportPeriod 2026-03-290000078003-26-000054
2026-05-0511:01 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0000078003-26-000053
2026-04-2721:16 ET8-K5.07 Shareholder vote results0000078003-26-000044
2026-03-1213:05 ETDEF 14AProxy statementPeriod 2026-04-230000078003-26-000033
2026-02-2617:44 ET10-KAnnual reportPeriod 2025-12-310000078003-26-000026
2026-02-1317:09 ETSCHEDULE 13D/AOwnership report, active investor, amended0000078003-26-000022

Latest annual report

Form 10-K for the fiscal year ended Dec 31, 2025Filed Feb 26, 2026. Its page lists the documents and the extracted sections, such as Business and Risk factors.

Forecast league

Q3 FY2026, the quarter ended 2026-09-28, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by [object Promise].Forecast this quarter

About the filer

CIK
78003
Tickers
PFE
Exchange
NYSE
SIC code
2834 Pharmaceutical Preparations
Sector
Healthcare
Fiscal year ends
Dec 31
Incorporated in
DE
Filer category
Large accelerated filer
Former names
PFIZER INC (to 2026-10-16)

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:20 ET. Listed shows no prices and gives no investment advice.